Higher fulvestrant doses prolonged survival in patients with advanced breast cancer

Share this content:

Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated data from the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial.

The CONFIRM trial is a randomized, double-blind, parallel-group, multicenter, phase III trial of postmenopausal women with estrogen receptor (ER)-positive advanced breast cancer that recurred or progressed following endocrine therapy. Between February 2005 and August 2007, researchers randomly assigned 736 women from 128 centers in 17 countries to 250 mg or 500 mg of fulvestrant and followed them until 75% of the patients died. At the time of analysis, 554 patients had died, 63 were lost to follow-up, and 16 had withdrawn consent.

“Of note, the improvement in survival with the higher dose of fulvestrant was achieved without increasing treatment toxicity. Indeed, the dose of 500 mg had the same toxicity profile as the 250-mg dose,” said Angelo Di Leo, MD, PhD, head of the department of medical oncology at the Hospital of Prato, Istituto Toscano Tumori in Prato, Italy.

Among the entire study population, the 500-mg dose was associated with a clinically relevant 4.1-month difference in median overall survival compared with the lower dose: 26.4 months in the 500-mg group and 22.3 months in the 250-mg group. Serious adverse events occurred in 8.9% of patients who had received the 500-mg dose and in 6.7% of patients in the 250-mg group.

“For those postmenopausal women with recurrent or progressing ER-positive locally advanced or metastatic breast cancer for whom fulvestrant is the appropriate treatment choice, the standard of care is a 250-mg dose,” said Di Leo. “Our results indicate that this should be modified to a 500-mg dose.”

According to Di Leo, the next research step will be to study 500 mg of fulvestrant in combination with biological agents, such as PI3K inhibitors or anti-HER2 agents that can reverse resistance to endocrine therapy.

“This approach could further increase the activity of fulvestrant given at the 500-mg dose,” Di Leo said.

This study was presented at the CRTC-AACR San Antonio Breast Cancer Symposium.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs